Parabilis Medicines
PBLS----
Parabilis Medicines (PBLS)
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The c...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Parabilis Medicines Analyst Rating
View MoreForecast & Rating
Jul 6, 2026Price forecast
$41.7531.99%
Forecast & RatingStrong buy
5analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 24 at 04:13 AM
Global capital pivots to idiosyncratic U.S. assets as macro headwinds intensify
- PUBT · Jul 23 at 11:40 PM
HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%
- Tip Ranks · Jul 22 at 09:01 PM
Major Insider Move Signals Growing Confidence in Parabilis Medicines
- PUBT · Jul 22 at 03:59 PM
RA Capital Management buys USD 6.84 million of Parabilis Medicines common shares
- Global Report · Jul 21 at 04:13 AM
Capital Rotations: A Record Biotech IPO and the Surging European Defense ETF
- Market Beat · Jul 13 at 12:20 AM
Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS)
